share_log

AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)

AbbVie | 8-K: Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited)

艾伯維公司 | 8-K:艾伯維公司指導方針包括收購的知識產權研發及里程碑費用的影響
美股SEC公告 ·  2024/10/04 04:12

Moomoo AI 已提取核心訊息

AbbVie announced that its Q3 2024 earnings will include an $82 million pre-tax expense for acquired IPR&D and milestones, impacting both GAAP and adjusted non-GAAP diluted EPS by $0.04. The company has revised its Q3 2024 adjusted diluted EPS guidance to $2.88-$2.92.Following this adjustment, AbbVie updated its full-year 2024 adjusted diluted EPS guidance range to $10.67-$10.87, incorporating the Q3 IPR&D expense impact. The total acquired IPR&D and milestone expenses for 2024 are now expected to reach $1.183 billion.The company noted that these results are preliminary and subject to financial statement closing procedures. Future IPR&D and milestone expenses beyond Q3 2024 are not included in the guidance due to uncertainty in timing and occurrence of such transactions.
AbbVie announced that its Q3 2024 earnings will include an $82 million pre-tax expense for acquired IPR&D and milestones, impacting both GAAP and adjusted non-GAAP diluted EPS by $0.04. The company has revised its Q3 2024 adjusted diluted EPS guidance to $2.88-$2.92.Following this adjustment, AbbVie updated its full-year 2024 adjusted diluted EPS guidance range to $10.67-$10.87, incorporating the Q3 IPR&D expense impact. The total acquired IPR&D and milestone expenses for 2024 are now expected to reach $1.183 billion.The company noted that these results are preliminary and subject to financial statement closing procedures. Future IPR&D and milestone expenses beyond Q3 2024 are not included in the guidance due to uncertainty in timing and occurrence of such transactions.
艾伯維公司宣佈,2024年第三季度的收益將包括8200萬美元的稅前費用,涉及獲得的知識產權和研發及里程碑費用,這將對GAAP和調整後的非GAAP攤薄後每股收益產生0.04美元的影響。該公司已將其2024年第三季度的調整後攤薄後每股收益指導意見修訂爲2.88美元至2.92美元。在這一調整之後,艾伯維公司更新了其2024年全年調整後攤薄後每股收益指導區間至10.67美元至10.87美元,其中包含了第三季度知識產權和研發費用的影響。2024年的總知識產權和研發及里程碑費用現預計將達到11.83億美元。該公司指出,這些結果屬於初步數據,並需遵循財務報表的關閉程序。由於時間和此類交易發生的不確定性,2024年第三季度以後的未來知識產權和研發及里程碑費用未包含在指導意見中。
艾伯維公司宣佈,2024年第三季度的收益將包括8200萬美元的稅前費用,涉及獲得的知識產權和研發及里程碑費用,這將對GAAP和調整後的非GAAP攤薄後每股收益產生0.04美元的影響。該公司已將其2024年第三季度的調整後攤薄後每股收益指導意見修訂爲2.88美元至2.92美元。在這一調整之後,艾伯維公司更新了其2024年全年調整後攤薄後每股收益指導區間至10.67美元至10.87美元,其中包含了第三季度知識產權和研發費用的影響。2024年的總知識產權和研發及里程碑費用現預計將達到11.83億美元。該公司指出,這些結果屬於初步數據,並需遵循財務報表的關閉程序。由於時間和此類交易發生的不確定性,2024年第三季度以後的未來知識產權和研發及里程碑費用未包含在指導意見中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息